Beijing: More measures to promote the growth of the bio-pharmaceutical industry

In the first quarter of this year, Beijing’s industrial enterprises above designated size realized an added value of RMB 50 billion, which was calculated at a comparable price, which was a decrease of 3.4% year-on-year. However, Beijing's pharmaceutical industry has completed a total industrial output value (current price) of 8.46 billion yuan, an increase of 34.9%, and sales revenue of 7.73 billion yuan, an increase of 16.5% over the same period last year, to achieve a total profit of 1.34 billion yuan, an increase of 10.3% over the same period last year.

Technological innovation supports the sustained and rapid growth of the biomedical industry.

Since 2004, the Beijing Municipal Commission of Science and Technology deepened the reform of the management system of science and technology, with the goal of comprehensively improving the ability of innovation of enterprises, and mobilized technological resources and promoted the cooperation of industry, university and research institute as means to fully activate biomedical enterprises' independent innovation capabilities on the one hand, and promoted on the other The establishment of an innovation system for leading pharmaceutical enterprises in Beijing.

In the past five years, the Municipal Science and Technology Commission has invested over 400 million yuan in financial science and technology in the field of biomedicine, established 23 major projects, and established the Beijing biomedical industry from drug design, pharmaceutical research, safety evaluation to formulation research and development, large-scale production, etc. Innovative research and development chain. The overall level of Beijing biopharmaceutical continues to increase, and the ability of independent innovation of enterprises has been significantly improved. Two types of new drugs independently researched and developed have been on the market, and five other independent innovation achievements have obtained clinical research approvals. The proportion of major projects for innovative drugs won by the productive enterprises is even higher. From 17% in 2004 to 100%, the biopharmaceutical industry has entered the fast track of rapid development.

New drug development potential "bombshell"

On March 25th, the latest progress in the clinical research of hemagglutinating drugs and a new type of drug "Sulin" was officially launched. As the first new drug for snake venom blood clotting enzymes in China, “Su Ling” has great replaceability for imported similar drugs that occupy a huge market share in China.

The Municipal Science and Technology Commission has organized major projects since 2002 and has adopted public bidding methods. It has successively supported 71 new drug development projects. Focusing on innovative drugs, we will cultivate key "seen" varieties, especially those that combine with the production enterprises in the Beijing area, concentrate their efforts on vigorous support, and enable the varieties to rapidly realize industrialization and form the future "pound bomb" of the pharmaceutical industry.

The listing of “Su Ling” marks that independent innovation will become the most effective means for the Beijing bio-pharmaceutical industry to actively respond to the financial crisis. With the promotion of a series of independent innovation achievements represented by Su Ling, Tai Xinsheng, hepatitis E vaccine, and tumor hyperthermia instrument, the Beijing biopharmaceutical industry has always maintained its growth momentum, becoming Beijing's “guaranteed growth, expansion of domestic demand, and adjustment”. "Structure" is an important force and is expected to contribute more to the steady and rapid development of the capital economy.

Innovation supports Beijing Dragon Pharmaceutical

In 2003 and 2005, the Science Committee of the Municipality, in response to the upgrading of famous and high-quality products of Tong Ren Tang and the scientific and technological needs of modern Chinese medicine in the production process, successively supported the development of the “Second Development of 10 Famous Prescriptions such as Liu Wei Di Huang” and “Manufacture of Chinese Herbal Preparations”. After several years of research and development, Tongren Tang completed the research on the formulation of the Tongren Wuji Baifeng Pills and the anti-effervescent effervescent tablets. It established a key technology platform for the production process of the formulation and realized the engineering. Production, production capacity increased by more than 50%, energy consumption reduced by 30%, production cycle shortened by more than 40%, production line operators reduced by 40%; product once qualified rate reached 100%, technology reached the domestic advanced level. Tong Ren Tang Group's annual sales revenue for the fifth consecutive year to maintain the country's first.

Build a pharmaceutical group innovation chain

In 2003, in order to improve the overall level of preparation technology in Beijing and build a company's innovation chain, with the Beijing Pharmaceutical Group as the core, organizations such as the Academy of Military Medical Sciences, Peking University and the Chinese Academy of Medical Sciences cooperated to carry out key technologies for large-scale production of controlled release formulations. , Launched a major project of “Research and Development of Slow-Release and Controlled Release Formulation Technologies”, and the subsidiaries of Shuanghe, Secco and Zizhu participated in the development of their varieties. Through three years of R&D, the Beijing Innovative Formula Research and Development Center has been established with the joint research of production, education and research, market mechanism operation, and open management; the establishment of a slow and controlled release technology platform has been completed, and corresponding industrial operating procedures and key technical parameters have been obtained. 6 clinical varieties were obtained; metformin hydrochloride sustained-release tablets, aripiprazole orally disintegrating tablets obtained a new drug certificate and has been listed. The implementation of the project laid a good foundation for North Pharmaceutical Group to build a formulation service and industrialization platform, promoted Beibei Pharmaceutical Group's innovation system construction, and accelerated its internationalization process. Currently, the group's subsidiaries represented by Shuanghe and Zizhu are In carrying out the international certification of its products.

In 2008, the pharmaceutical preparation pilot plant established by the China National Pharmaceutical Research and Development Center Co., Ltd. passed the national GMP certification to further strengthen its market service capabilities, and at the same time address the needs of small and medium-sized enterprises in preparation of new drug research and development pilot services, improve the efficiency of new drug development and With the industrialization of results, in 2009 the Municipal Science and Technology Commission launched a major project of “Building Innovation Synergy Promotion Action—Formation of a Formulation Pilot-testing Technology Service Platform” and adopts a method of “pairing” with enterprises, integrating relevant resources, and conducting preparations and pilot tests. R&D services to improve the level of innovation in Beijing Chemical Pharmaceuticals.

Docking national major projects

At the beginning of 2008, the Science and Technology Commission of the country initiated a major project of the “Major New Drug Creation System” in the country, combined with Beijing’s strategy for the development of science and technology, and initiated the “Beijing New Drug R&D System Innovation Service Platform” and “Beijing Biomedical S&T Innovation Enterprise Incubator Base Construction” project. The company has invested 30 million yuan in scientific and technological funding, and organized research and development service companies in the Beijing region to form a comprehensive national platform in the form of the China Biotechnology Outsourcing Service Alliance (ABO Alliance). It also organizes related research institutes, universities and enterprises in Beijing. More than 200 agencies report. The “Incubation Base Construction for New Enterprises” project was jointly declared by Zhongguancun Biopharmaceuticals Park, Shuanglu Pharmaceutical and Beijing Kexing; and the national major project of “Prevention and control of major communicable diseases such as AIDS and viral hepatitis” was formed by members of the ABO Alliance. The company, China-U.S. Ouda and Kain Corporation jointly applied for the “Infectious Disease Vaccine Development Technology Research and New Vaccine Development” project. Taking the opportunity to connect with major national projects, through the implementation of the project, Beijing has accelerated the pace of internationalization of the service standards of Beijing's medical R&D service industry and laid a foundation for the expansion of Beijing's pharmaceutical industry.